Description

PA007163.m1: Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone 29F.1A12.1), Mouse IgG1 Kappa, In Vivo Grade

Background

The rat anti-mouse PD-1 monoclonal antibody 29F.1A12 (rat IgG2a kappa) reacts with the mouse PD-1 protein (programmed death-1 or CD279) encoded by the mouse Pdcd1 gene, a member of the CD28 family of the Ig superfamily. PD-1 has two ligands, PD-L1 and PD-L2, both of which belong to the B7 family. It has been shown that in mouse models of melanoma, tumor growth can be transiently arrested via treatment with the anti-mouse PD-1 and anti-mouse PD-L1 antibodies which block the interaction between the PD-L1 protein and its receptor PD-1 protein. The 29F.1A12 monoclonal antibody blocks the binding of both the mouse PD-L1 protein and the mouse PD-L2 protein to the mouse PD-1 protein.

Our recombinant 29F.1A12 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse PD-1 monoclonal antibody (hybridoma clone name or number: 29F.1A12).

References of Anti-mouse PD-1 Monoclonal Antibody (Clone: 29F.1A12)

1. Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells.
Martins C, et al. J Immunother Cancer. 2022 Jul;10(7):e004655. PMID: 35858688; PMCID: PMC9304406
“Flow cytometric analyses with two separate anti-PD-1 ab clones, 29F.1A12 and RMP1-30, revealed PD-1 surface protein expression on live murine melanoma cells. Recombinant PD-L1 also recognized melanoma cell-expressed PD-1, the blockade of which by 29F.1A12 fully abrogated PD-1:PD-L1 binding. Together, our data provides multiple lines of evidence establishing PD-1 expression by live murine melanoma cells and validates ab clones and assay systems for tumor cell-directed PD-1 pathway investigations.”

2. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.
F. P., et al. J Immunother Cancer. 2020 Oct;8(2):e001306. PMID: 33055177; PMCID: PMC7553530
“In preclinical studies, the PD1-Vaxx outperformed the standard anti-mouse PD-1 antibody (mAb 29F.1A12) in a mouse model of human HER-2 expressing colon carcinoma. We obtained enhanced inhibition of tumor growth in a syngeneic BALB/c model challenged with colon carcinoma cell line CT26/HER-2 which outperformed the standard anti-mouse PD-1 mAb (29F.1A12). The vaccine construct effectively triggers an immune response that mimics the efficacy of monoclonal antibody checkpoint inhibition.”

3. Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses.
T. A., et al. Cancers (Basel). 2021 Nov 25;13(23):5926. PMID: 34885002; PMCID: PMC8642283
“Lysates were made from the indicated cell lines and Western blotted with antibodies against phospho–PD-1 (6G12), mPD-1 (29F.1A12), and GAPDH. One mAb clone (407.6G12) detected a band only in pervanadate-treated, PD-1+ samples, and this band corresponded in size to PD-1. These results show that mAb 407.6G12 can detect the phosphorylated form of the PD-1 ITSM by both Western blot and flow cytometry.”

4. Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells.
G. L., et al. JCI Insight. 2023 Feb 8;8(3):e155986. PMID: 36752077; PMCID: PMC9905221
“PD-1 deficiency was associated with an increased neutrophilic airway hyperreactivity and high recruitment of inflammatory cells to the lungs. Consistently, PD-1 agonist treatment dampened airway hyperreactivity, decreased neutrophil recruitment, and modulated cytokine production in a humanized PD-1 mouse model. Mechanistically, we demonstrated that the inhibitory effect of PD-1 agonist is associated with the reprogramming of pulmonary effector T cells.”

5. Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys).
P. A., et al. Vaccines (Basel). 2022 May 6;10(5):737. PMID: 35632490; PMCID: PMC9137037
“Cancer vaccines have the ability to stimulate the native immune system and an engineered B-cell epitope can elicit high-affinity polyclonal antibodies with similar efficacy to PD-1 monoclonal antibodies in murine animal models. We designed and synthesized a unique B-cell vaccine, PD1-Vaxx, and tested the immunogenicity and antitumor properties in CT26 colon cancer BALB/c syngeneic mice model. The results suggest the vaccine has acceptable pharmacology and immunogenicity profiles to justify initiating clinical trials.”

For more technical references or data sheets regarding the Anti-mouse PD-1 Monoclonal Antibody (Clone: 29F.1A12) formats, please contact our scientific support team at message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
Recombinant Mouse IgG1 Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Mouse IgG2a Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Mouse IgG2c Isotype Control Antibody and Mutants, In vivo Grade
Recombinant Rat IgG2b Isotype Control Antibody, In vivo Grade

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
Recombinant anti-mouse PD1 antibodies (Clone 29F.1A12.1), In vivo grade
Recombinant anti-mouse PD-1 antibodies (Clone RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-L1 antibodies (Clone 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone RMP1-14.1 / 29F.1A12.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone 29F.1A12.1 / RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone RMP1-14.1 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / RMP1-14.1), In vivo grade
Recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone 29F.1A12.1 / 10F.9G2.1), In vivo grade
Recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / 29F.1A12.1), In vivo grade

Questions and Answers about anti-mouse PD-1 antibody (Clone 29F.1A12):

Question: Which anti-mouse PD1 antibody works the best?
Answer: (by AI) There are several anti-mouse PD1 antibodies available in the market. Bio X Cell offers three different anti-mouse PD-1 monoclonal antibodies: Clones RMP1-14, 29F.1A12, and J43. All three of these antibodies are commonly used to block PD-1 signaling in vivo in murine tumor models and other mouse models. These three clones all have extensive multi-year publication records supporting them. Leinco Technologies offers four different anti-PD-1 monoclonal antibodies: 29F.1A12, RMP1-14, J43, and 5C4-B83. The RMP1-14 antibody has been reported to block the binding of PD-1 to its ligands (B7-H1 and B7-DC) and to inhibit T cell proliferation and cytokine production costimulated by macrophages (but not by dendritic cells and B cells). (by Syd Labs) Syd Labs offers anti-mouse PD-1 / CD279 monoclonal antibodies based on the sequences of clones RMP1-14 and 29F.1A12. Syd Labs provides in vivo grade recombinant antibodies including engineered antibodies for the clones RMP1-14 and 29F.1A12.

Question: Do you produce Fc-silenced 29F.1A12 antibody?
Answer: We provide recombinant 29F.1A12 antibodies including the Fc-silenced or Fc silent versions of recombinant 29F.1A12 antibodies. It is very easy for us to produce the Fc-silenced or Fc silent versions of recombinant 29F.1A12 antibodies no matter which isotypes they are based, for example, mIgG2c LALAPG.

Question: What are the published applications of the 29F.1A12 antibody?
Answer: It was reported that the blockade of the PD-1 protein expressed on TME-infiltrating macrophages and natural killer (NK) cells by 29F.1A12 results in tumor growth suppression and prolonged survival. It is also reported that the 29F.1A12 antibody recognizes the PD-1 surface protein on B16-F10 and other murine tumor lines, suppresses cancer cell-intrinsic PD-1 receptor signaling, and inhibits resultant tumor growth in three-dimensional (3D) culture and tumor-bearing mice. In the paper “Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells”, it was shown that the anti-PD-1 29F.1A12 monoclonal antibody recognizes the PD-1 surface protein on live B16-F10 melanoma cells, live YUMM melanoma variant lines, and overlapping WT murine B16-F10 and YUMM melanoma and T-cell subsets by FACS. In contrast to the RMP1-30 antibody, The 29F.1A12 PD-1 blocking antibody inhibits PD-1 interactions with PD-L1 on live B16-F10 melanoma cells. The RMP1-14 clone, but not 29F.1A12 or RMP1-30, is useful for pulling down (IP) and sequencing PD-1 from B16-F10 and T-cell cultures, consistent with the previous observations that individual antibodies differ in their suitability for specific assay types. 29F.1A12 binding to B16-F10 cells was increased in 3D versus 2D settings.

Anti-mouse PD-1 Antibody (29F.1A12.1) from: In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG1 Kappa Monoclonal Antibody (Clone 29F.1A12.1): PA007163.m1 Syd Labs